Cargando…

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

PURPOSE OF REVIEW: In 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP). This review updates the reader on PARP function, the development of PARP inhibitors (PARPi) and the evidence for targeting PARP in Ewing sarc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vormoor, Britta, Curtin, Nicola J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	SARCOMAS: Edited by Jonathan C. Trent
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059819/ https://www.ncbi.nlm.nih.gov/pubmed/24840521 http://dx.doi.org/10.1097/CCO.0000000000000091

Ejemplares similares

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2
por: Vormoor, Britta, et al.
Publicado: (2017)

Atrial Thrombus Mimicking Ewing's Sarcoma
por: Hon, Matthew, et al.
Publicado: (2019)

Saving the hand: Role of multimodality therapy for Ewing's sarcoma family tumor of the palm
por: Joseph, Sanjay A., et al.
Publicado: (2018)

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two‐Cohort, Phase Ib/II Trial
por: Xu, Jie, et al.
Publicado: (2021)

Emerging Trends in Immunotherapy for Adult Sarcomas
por: Husain, Marium, et al.
Publicado: (2023)

Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
por: Martin‐Broto, Javier, et al.
Publicado: (2020)

Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma
por: Massoth, Lucas R., et al.
Publicado: (2021)

Soft Tissue Sarcoma of Lower Extremity: Functional Outcome and Quality of Life
por: Kask, Gilber, et al.
Publicado: (2021)

Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

MRI Radiomic Features Are Independently Associated With Overall Survival in Soft Tissue Sarcoma
por: Spraker, Matthew B., et al.
Publicado: (2019)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Early symptoms of bone and soft tissue sarcomas: could they be diagnosed earlier?
por: George, A, et al.
Publicado: (2012)

Management of Soft Tissue Sarcomas in Extremities: Variation in Treatment Recommendations and Surveillance According to Specialty and Continent
por: Acem, Ibtissam, et al.
Publicado: (2021)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Impact of treatment protocol on outcome of localized Ewing's sarcoma
por: Nasaka, Srividya, et al.
Publicado: (2016)

Unplanned Excision of Soft Tissue Sarcomas of the Extremities in a Low-to-Middle-Income Country
por: Wang, Edward H. M., et al.
Publicado: (2023)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Frailty in Very Elderly Patients is Not Associated with Adverse Surgical or Oncological Outcomes in Extremity Surgery for Soft Tissue Sarcoma
por: Sivarajah, Gausihi, et al.
Publicado: (2022)

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023)

Efficacy of Trabectedin in Patients with Advanced Translocation‐Related Sarcomas: Pooled Analysis of Two Phase II Studies
por: Takahashi, Mitsuru, et al.
Publicado: (2017)

Neoadjuvant Chemoradiation Compared With Neoadjuvant Radiation Alone in the Management of High-Grade Soft Tissue Extremity Sarcomas
por: Hazell, Sarah Z., et al.
Publicado: (2019)

Functional Outcome Measurement in Patients with Lower-Extremity Soft Tissue Sarcoma: A Systematic Literature Review
por: Kask, Gilber, et al.
Publicado: (2019)

Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?
por: Plummer, R
Publicado: (2011)

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Current status of poly(ADP-ribose) polymerase inhibitors and future directions
por: Ohmoto, Akihiro, et al.
Publicado: (2017)

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
por: Boussios, Stergios, et al.
Publicado: (2020)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020)

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

Late Local Recurrence and Metastasis in Soft Tissue Sarcoma of the Extremities and Trunk Wall: Better Outcome After Treatment of Late Events Compared with Early
por: von Konow, Arvid, et al.
Publicado: (2021)

One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
por: Flores, Guillermo, et al.
Publicado: (2021)

Role of poly(ADP-ribose) polymerases in male reproduction
por: Celik-Ozenci, Ciler, et al.
Publicado: (2013)

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma
por: Chugh, Rashmi, et al.
Publicado: (2020)

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.
por: Boulton, S., et al.
Publicado: (1995)

Antidepressant-Like Actions of Inhibitors of Poly(ADP-Ribose) Polymerase in Rodent Models
por: Ordway, Gregory A, et al.
Publicado: (2017)

Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064.
por: Bowman, K. J., et al.
Publicado: (1998)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer
por: Zhang, Jingsong
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_suk1uagut2so2j4s5l7sgrj911